dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2015-12-07T15:34:38Z
dc.date.available2015-12-07T15:34:38Z
dc.date.created2015-12-07T15:34:38Z
dc.date.issued2015
dc.identifierInternational Journal Of Nanomedicine, v. 10, p. 4981-5003, 2015.
dc.identifier1178-2013
dc.identifierhttp://hdl.handle.net/11449/131384
dc.identifier10.2147/IJN.S87148
dc.identifierPMC4531021.pdf
dc.identifier9129780536724256
dc.identifier26345528
dc.identifierPMC4531021
dc.description.abstractAlzheimer's disease is a neurological disorder that results in cognitive and behavioral impairment. Conventional treatment strategies, such as acetylcholinesterase inhibitor drugs, often fail due to their poor solubility, lower bioavailability, and ineffective ability to cross the blood-brain barrier. Nanotechnological treatment methods, which involve the design, characterization, production, and application of nanoscale drug delivery systems, have been employed to optimize therapeutics. These nanotechnologies include polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, microemulsion, nanoemulsion, and liquid crystals. Each of these are promising tools for the delivery of therapeutic devices to the brain via various routes of administration, particularly the intranasal route. The objective of this study is to present a systematic review of nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease.
dc.languageeng
dc.publisherInternational Journal Of Nanomedicine
dc.relationInternational Journal Of Nanomedicine
dc.relation4.370
dc.relation1,225
dc.rightsAcesso aberto
dc.sourcePubMed
dc.subjectAlzheimer’s disease
dc.subjectLiquid crystals
dc.subjectMicroemulsions
dc.subjectNose-to-brain
dc.subjectPolymeric nanoparticles
dc.subjectSolid lipid nanocarriers
dc.subjectTargeted delivery
dc.titleNanotechnology-based drug delivery systems for the treatment of Alzheimer's disease
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución